Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Poignard

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
Immunity|April 29, 2014
Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimersEmilia Falkowska, Khoa M Le, Alejandra Ramos, et al.
Nature|February 25, 2015
AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challengesMatthew R Gardner, Lisa M Kattenhorn, Hema R Kondur, et al.
The Journal of Infection|February 17, 2024
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trialMaya Hites, Clément R Massonnaud, Eva Larranaga Lapique, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 22, 2025
Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in hospitalized COVID-19 patients: long-term results from the DisCoVeRy trialClément R Massonnaud, Nathan Peiffer-Smadja, Pascal Poignard, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
Immunity|April 29, 2014
Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimersEmilia Falkowska, Khoa M Le, Alejandra Ramos, et al.
Nature|February 25, 2015
AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challengesMatthew R Gardner, Lisa M Kattenhorn, Hema R Kondur, et al.
The Journal of Infection|February 17, 2024
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trialMaya Hites, Clément R Massonnaud, Eva Larranaga Lapique, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 22, 2025
Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in hospitalized COVID-19 patients: long-term results from the DisCoVeRy trialClément R Massonnaud, Nathan Peiffer-Smadja, Pascal Poignard, et al.
Pageof 9